RecruitingType 2 Diabetes

Ultrasound Effects on Glycemic Control in T2DM

Eligible age

21–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.

Sponsor: Yale University

You may qualify if…

✓ 1. Male or female subjects with a diagnosis of type 2 diabetes ≥ 3 months.
✓ 2. Age ≥ 21 and ≤ 75 years.
✓ 3. Currently on a stable treatment regimen of oral anti-diabetic drugs and not currently prescribed for medication escalation. Oral anti-diabetic drugs are limited to one or more of the following:
✓ Metformin
✓ Sulfonylureas
✓ Meglitinides
✓ Thiazolidinediones
✓ 4. HbA1c \> 7.0% and \< 10% by local laboratory analysis.

You may not qualify if…

✕ 1. History or current diagnosis with T1DM or T2DM subjects on insulin, DPP-4 inhibitors, GLP agonists.
✕ 2. A subject who is already indicated for medication escalation of their current diabetic therapy.
✕ 3. A subject who has manifestations of advanced complications from poorly controlled or longstanding diabetes such as diabetic retinopathy, diabetic neuropathy and cardiovascular complications including, but not limited to coronary artery disease, peripheral vascular disease, or cerebrovascular disease such as transient ischemic attack \[TIA\], cerebral infarct, or cerebral hemorrhage.
✕ 4. History or current diagnosis of cardiac dysrhythmias or heart disease, defined as symptomatic heart failure (New York Heart Association class III or IV), myocardial infarction, unstable angina requiring medication.
✕ 5. Invasive cardiovascular procedure, such as coronary artery bypass graft surgery (CABG), or angioplasty/percutaneous coronary intervention (PCI) within 6 months of screening.
✕ 6. History of recurrent severe hypoglycemia (more than 1 event ≤ 6 month)
✕ 7. Subjects with clinically active malignancy
✕ 8. History of renal disease or abnormal kidney function tests at Screening (glomerular filtration rate \[GFR\] \< 60 mL/min/1.73m2 as estimated using the MDRD equation).

Where it's recruiting

Connecticut

New Haven

Source: ClinicalTrials.gov · NCT05354947 · last updated 2026-01-27